RTP Mobile Logo
Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer (Faculty Presentations)
Released May 2020

Featuring slide presentations from Drs Hossein Borghaei, Julie R Brahmer, Edward B Garon, Ramaswamy Govindan, John V Heymach, Leora Horn, Melissa L Johnson and Benjamin Levy. (Video Program)

CE Disclosures and Faculty Information

    This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

    Lung cancer is a devastating disease with a broad impact on public health as it accounts for 13% of all new cancer cases in the Unites States and the most cancer-related deaths among both men and women. The last several years have seen an explosion in the emergence of new therapies, including immunotherapies and targeted therapies, that have transformed the treatment of metastatic non-small cell lung cancer (NSCLC), but although these therapies have been shown to improve overall survival, they have also led to changes in the prevailing treatment algorithms and new challenges in the management of this disease. In order to offer optimal patient care, clinicians must be well informed of these advances.

    This CME program features presentations by leading lung cancer experts on the optimal clinical care of patients with metastatic NSCLC. By reviewing the available clinical trial data, this initiative will provide insight into the gaps in medical knowledge and illuminate treatment ambiguities.


    • Consider emerging research information in the development of a biomarker testing algorithm to optimize first- and later-line therapy for individuals with NSCLC.
    • Evaluate available and emerging clinical research supporting the roles of chemotherapy, biologic therapy, immunotherapy and combination approaches in the management of locally advanced or metastatic NSCLC.
    • Review recent therapeutic advances in the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy for metastatic NSCLC, and discern how these approaches can be optimally employed in clinical practice.
    • Consider performance status, prior therapeutic exposure, disease-free interval and other patient- and disease-related factors in the selection of systemic therapy for patients with metastatic NSCLC in the first- and second-line settings.
    • Appraise available data, existing guideline recommendations and expert perspectives regarding the selection and sequencing of available therapeutic options for patients with NSCLC and targetable alterations.
    • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and discern how available and investigational therapies can be optimally employed in the care of patients with progressive NSCLC with EGFR mutations.
    • Appreciate available clinical trial data documenting the efficacy of ramucirumab in patients with metastatic NSCLC, and consider how this agent can be integrated into lung cancer clinical practice.
    • Develop strategies to recognize and manage toxicities associated with immune checkpoint inhibitors and targeted therapies.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/LungCancerSummit20/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Hossein Borghaei, DO, MS
    Professor and Chief, Thoracic Oncology
    The Gloria and Edmund M Dunn Chair in Thoracic Oncology
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Genmab, Lilly, Merck, Novartis, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Axiom Life Sciences Group LLC, Bristol-Myers Squibb Company, HUYA Bioscience International, Lilly, Merck; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board/Committee: Incyte Corporation, Takeda Oncology, University of Pennsylvania, Vanderbilt University; Scientific Advisory Board: Rgenix, Sonnet BioTherapeutics.

    Julie R Brahmer, MD, MSc
    Professor of Oncology
    Director of the Upper Aerodigestive Cancer Disease Program
    Co-Director of the Cancer Immunology Program
    Co-Director of the Upper Aerodigestive Cancer Program at
    Bloomberg-Kimmel Institute for Cancer Immunotherapy
    Director of the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview Campus
    The Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Medicine
    Baltimore, Maryland

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company (uncompensated), Genentech, a member of the Roche Group, GlaxoSmithKline, Lilly, Merck; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Sanofi Genzyme; Contracted Research: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, RAPT Therapeutics, Revolution Medicines; Data and Safety Monitoring Board/Committee: GlaxoSmithKline, Sanofi Genzyme.

    Edward B Garon, MD, MS
    Associate Professor
    Director, Thoracic Oncology Program
    Director, Signal Transduction and Therapeutics Research Program
    David Geffen School of Medicine at UCLA
    Jonsson Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee: Dracen Pharmaceuticals, EMD Serono Inc, GlaxoSmithKline, Mirati Therapeutics, Novartis; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis.

    Ramaswamy Govindan, MD
    Professor of Medicine
    Director, Section of Oncology
    Anheuser-Busch Endowed Chair in Medical Oncology
    Washington University School of Medicine
    St Louis, Missouri

    Advisory Committee: AbbVie Inc, Achilles Therapeutics; Consulting Agreement: Amgen Inc.

    John V Heymach, MD, PhD
    Professor and Chair
    Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AstraZeneca Pharmaceuticals LP, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, EMD Serono Inc, Foundation Medicine, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Kairos Venture Investments LLC, Lilly, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Hengrui Therapeutics Inc, Kairos Venture Investments LLC, Lilly; Contracted Research: AACR-Johnson & Johnson Lung Cancer Innovation Science Grants, American Cancer Society, AstraZeneca Pharmaceuticals LP, Cancer Prevention & Research Institute of Texas, Checkmate Pharmaceuticals, National Cancer Institute at the National Institutes of Health, Spectrum Pharmaceuticals Inc; Patents and Royalties: Bio-Tree Systems Inc, Spectrum Pharmaceuticals Inc.

    Leora Horn, MD, MSc
    Ingram Associate Professor of Cancer Research
    Director, Thoracic Oncology Research Program
    Assistant Vice Chairman for Faculty Development
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Advisory Committee: Amgen Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Xcovery; Consulting Agreements: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Xcovery; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Xcovery.

    Melissa L Johnson, MD
    Associate Director, Lung Cancer Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements: AbbVie Inc, Achilles Therapeutics, AstraZeneca Pharmaceuticals LP, Atreca, Boehringer Ingelheim Pharmaceuticals Inc, Calithera Biosciences, Genentech, a member of the Roche Group, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Incyte Corporation, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Ribon Therapeutics, Sanofi Genzyme; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Amgen Inc, Apexigen, Arcus Biosciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Atreca, BeiGene, BerGenBio ASA, Boehringer Ingelheim Pharmaceuticals Inc, Calithera Biosciences, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals, CytomX Therapeutics, Daiichi Sankyo Inc, Dynavax Technologies Corporation, EMD Serono Inc, Genentech, a member of the Roche Group, Genmab, Genocea Biosciences Inc, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Hengrui Therapeutics Inc, Immunocore, Incyte Corporation, Janssen Biotech Inc, Jounce Therapeutics, Lilly, Merck, Mirati Therapeutics, Neovia Oncology, Novartis, OncoMed Pharmaceuticals Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Ribon Therapeutics, Sanofi Genzyme, Seven and Eight Biopharmaceuticals Inc, Shattuck Labs, Stemcentrx, Syndax Pharmaceuticals Inc, Takeda Oncology, Tarveda Therapeutics, TCR2 Therapeutics, University of Michigan, WindMIL Therapeutics.

    Benjamin Levy, MD
    Associate Professor, Johns Hopkins School of Medicine
    Clinical Director, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial
    Medical Director, Thoracic Oncology Program
    Washington, DC

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc, Takeda Oncology; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Lilly.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: May 2020
    Expiration date: May 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):